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Abstract
Portopulmonary hypertension affects up to 6% of patients with advanced liver disease, but the
predictors and biologic mechanism for the development of this complication are unknown. We
sought to determine the clinical risk factors for portopulmonary hypertension in patients with
advanced liver disease. We performed a multicenter case-control study nested within a prospective
cohort of patients with portal hypertension recruited from tertiary care centers. Cases had a mean
pulmonary artery pressure >25 mm Hg, pulmonary vascular resistance >240 dynes · second ·
cm−5, and pulmonary capillary wedge pressure ≤ 15 mm Hg. Controls had a right ventricular
systolic pressure < 40 mm Hg (if estimable) and normal right-sided cardiac morphology by
transthoracic echocardiography. The study sample included 34 cases and 141 controls. Female sex
was associated with a higher risk of portopulmonary hypertension than male sex (adjusted odds
ratio =2.90, 95% confidence interval 1.20-7.01, P = 0.018). Autoimmune hepatitis was associated
with an increased risk (adjusted odds ratio = 4.02, 95% confidence interval 1.14-14.23, P = 0.031),
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and hepatitis C infection was associated with a decreased risk (adjusted odds ratio =0.24, 95%
confidence interval 0.09-0.65, P =0.005) of portopulmonary hypertension. The severity of liver
disease was not related to the risk of portopulmonary hypertension.
Conclusion—Female sex and autoimmune hepatitis were associated with an increased risk of
portopulmonary hypertension, whereas hepatitis C infection was associated with a decreased risk
in patients with advanced liver disease. Hormonal and immunologic factors may therefore be
integral to the development of portopulmonary hypertension.
Pulmonary arterial hypertension (PAH) is a progressive disease which is characterized by
elevated pulmonary vascular resistance, right heart failure, exercise limitation, and an
increased risk of death. Histopathologic examination reveals intimal proliferation, medial
hypertrophy, and adventitial fibrosis in the small muscular pulmonary arteries. Plexiform
lesions and in situ thrombosis are also commonly seen. Most commonly idiopathic, PAH
may also be associated with portal hypertension, termed portopulmonary hypertension
(PPHTN). McDonnell et al. showed a prevalence of histopathologic changes of PAH in
0.61% of autopsies of patients with cirrhosis, and PPHTN was the third most common form
of PAH in a population-based epidemiologic study in France.1,2 Recent cohort studies
showed a prevalence of PPHTN of 5%-6% in patients presenting for liver transplant
evaluation.3-5 Patients with PPHTN have an increased risk of death, even with specific PAH
treatment.4,6 In many cases, PPHTN greatly complicates or precludes liver transplantation,
significantly affecting the course of hepatic failure in these patients.7,8
There are no known clinical factors which determine the risk of PPHTN in patients with
advanced liver disease. Similarly, the mechanism for pulmonary vascular obliteration in
patients with portal hypertension (characterized by systemic vasodilation) is unknown. It
follows that the identification of patient characteristics that increase or decrease the
probability of developing PPHTN might not only be clinically useful, but could also shed
light on the etiology of this relatively common comorbidity of portal hypertension.
Therefore, we studied whether demographics, type and severity of underlying liver disease,
or other patient factors were associated with the risk of PPHTN.
Patients and Methods
Study Design and Study Sample
The Pulmonary Vascular Complications of Liver Disease (PVCLD) Study prospectively
enrolled a cohort of 536 patients evaluated for liver transplantation or pulmonary
hypertension at seven centers in the United States between 2003 and 2006. The only
inclusion criterion was the presence of clinical portal hypertension with or without intrinsic
liver disease. We excluded patients with evidence of active infection or recent (less than 2
weeks) gastrointestinal bleeding, or who had undergone liver or lung transplantation.
Patients in the prospective cohort were newly referred for evaluation for liver transplantation
or pulmonary hypertension. We also included patients in the cohort who had been diagnosed
with PPHTN and treated before the beginning of the study (“prevalent” patients).
We performed a case-control study nested within the prospectively-assembled PVCLD
cohort. The study sample included newly referred patients who were evaluated with
transthoracic echocardiography (routinely performed for pretransplant evaluation) during the
study period. “Prevalent” patients who met the case definition (see below) were also
included. We excluded patients with significant obstructive lung disease, defined as forced
expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <0.70 with FEV1 percent
predicted <80%, and patients with a significant restrictive ventilatory defect, defined as FVC
percent predicted and (if performed) total lung capacity percent predicted < 70%. Patients
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who otherwise fulfilled the case definition (see below) without available pulmonary function
testing were included if chest radiography showed neither significant hyperinflation nor
interstitial lung disease; controls without pulmonary function testing were excluded. The
study sample also excluded patients with human immunodeficiency virus infection or the
presence of more than moderate aortic or mitral stenosis or regurgitation or significant left
ventricular dysfunction determined by transthoracic echocardiography.
Case and Control Definitions
Cases with PPHTN met the following criteria at initial evalution: (1) mean pulmonary artery
pressure >25 mm Hg, pulmonary capillary wedge pressure (or left ventricular end-diastolic
pressure) ≤ 15 mm Hg, and pulmonary vascular resistance > 240 dynes · second · cm−5
measured by right heart catheterization, and (2) no other etiology for pulmonary
hypertension. Controls met the following echocardiographic criteria at entry into the cohort:
(1) right ventricular (RV) systolic pressure < 40 mm Hg (if estimable) and (2) absence of
right atrial or ventricular dilation, hypertrophy, or dysfunction. Data from the initial
evaluation (before treatment) were used in analysis of “prevalent” cases. It was
recommended that right heart catheterization should be performed for patients with RV
systolic pressure > 50 mm Hg with abnormal RV morphology by echocardiography.
Sensitivity analyses included both patients who met the case definition but who had
pulmonary capillary wedge pressure between 16 and 19 mm Hg as cases and patients who
met the control definition but who had abnormal right atrial or ventricular morphology and/
or RV systolic pressure < 50 mm Hg (if estimable) as controls. We also performed a subset
analysis with cases who presented for their initial evaluation during the study period.
Potential Predictors
Data were collected from the patients and from the medical record. The etiology of
underlying liver disease (or portal vein thrombosis), past medical history, and social history
were recorded. Patients underwent a physical examination that included anthropometry,
blood pressure measurements, and laboratory assessment. The Model for End-Stage Liver
Disease (MELD) score was calculated.9
Other Variables
Chest radiography and computed tomography were interpreted locally at each center. The
results of the abdominal imaging study closest to the day of initial evaluation (computed
tomography, magnetic resonance imaging, or ultrasound) were recorded. Spirometry, lung
volumes, and diffusing capacity for carbon monoxide were measured; results are expressed
using standard sex-specific and race-specific prediction equations, where appropriate.10-12
Arterial blood gas was obtained, and the alveolar-arterial oxygen gradient was calculated.
Transthoracic echocardiography was interpreted at each center. Injection of agitated saline
was performed through a peripheral vein; an intrapulmonary shunt was considered present if
appearance of micro-bubbles in the left atrium occurred three or more cardiac cycles after
opacification of the right side of the heart. The study was approved by the Institutional
Review Board of each center, and patients provided informed consent before undergoing
study procedures.
Statistical Analyses
Continuous data were summarized using mean ± standard deviation or median (interquartile
range), as appropriate. Categorical variables were summarized using n (%). Bivariate
logistic regression was performed with case/control status as the dependent variable and
potential predictors as independent variables with results expressed as odds ratios (ORs).
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Multivariate logistic regression was performed including all variables which had P value <
0.20 on bivariate analysis or were hypothesized to predict case status. With the number of
cases, we determined that the final multivariate model should include four or fewer
predictors to prevent overfitting. Unpaired Student t tests, Wilcoxon rank sum tests, chi-
squared tests, and Fisher’s exact tests were used for other analyses, as appropriate.
The final multivariate model was assessed using the Hosmer-Lemeshow goodness-of-fit
test; dbetas were calculated to assess for influential subjects. All analyses were performed
with available data without imputation using Stata/IC version 10.0 (StataCorp, College Park,
TX). A two-sided P value of < 0.05 was considered statistically significant.
Results
There were 34 cases and 141 controls in the study sample. The mean age of the patients was
53 ± 9 years, and 44% were female. A total of 76% were non-Hispanic white, 13% were
Hispanic white, and 5% were non-Hispanic black. Patients with PPHTN had a mean right
atrial pressure of 10 ± 7 mm Hg, a mean pulmonary artery pressure of 49 ± 9 mm Hg, and
pulmonary capillary wedge pressure (or left ventricular end-diastolic pressure) of 10 ± 3 mm
Hg by right heart catheterization. The mean cardiac output was 5.4 ±1.8 L/minute, the
cardiac index was 2.8 ± 0.9 L/minute/m2, and the pulmonary vascular resistance was 696 ±
397 dynes · second · cm−5. Mean pulmonary artery oxygen saturation was 65 ±11% (N =
31).
Bivariate Analyses
Cases and controls were similar in terms of age and race/ethnicity (Table 1). Cases with
PPHTN were significantly more likely to be female than liver disease controls (OR = 3.98,
95% confidence interval 1.77-8.98, P = 0.001). Almost half of the cases and controls had
liver disease attributable to alcohol use. Cases with PPHTN were significantly less likely
than liver disease controls to be infected with hepatitis C, whereas they were significantly
more likely to have autoimmune hepatitis (both P ≤ 0.001). Patients with PPHTN were also
somewhat more likely to have primary biliary cirrhosis than controls, however, this was not
statistically significant. There was no association between case/control status and the
prevalence of nonalcoholic fatty liver disease, hepatitis B infection, primary sclerosing
cholangitis, or cryptogenic cirrhosis. There were fewer than three patients in each group
with primary portal vein thrombosis (one case), alpha-1 antitrypsin deficiency (one case,
two controls), biliary atresia (one control), or sarcoid (one case). Patients in the study sample
may have had more than one etiology of liver disease. One patient with PPHTN (3%) was
receiving interferon therapy as were five (4%) liver disease controls (P = 1.0).
The median time from diagnosis of the underlying liver disease to evaluation at the study
center was 6 years for cases and 3 years for controls (P = 0.04, N = 162). The mean MELD
score was 12 ± 4 and 13 ± 5 in cases and controls, respectively (P = 0.81). A total of 34% of
PPHTN cases and 36% of controls had mild liver disease (MELD score ≤ 10), and there was
no association between the presence of mild liver disease and PPHTN case status (P = 1.0).
Similarly, there were no associations between mean pulmonary artery pressure or pulmonary
vascular resistance and age, sex, or MELD score in patients with PPHTN (data not shown).
Cases with PPHTN were less likely than liver disease controls to have a history of ascites
and possibly less likely to have a history of encephalopathy, but there were no differences
between the groups in terms of other complications of liver disease or portal hypertension
(Table 2). A transjugular intrahepatic portosystemic shunt (or surgical shunt) was placed in
3% of cases and 6% of controls (P = 0.53) The prevalence of chronic obstructive pulmonary
disease, diabetes mellitus, hypertension and other medical conditions were similar between
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the groups. Most cases and controls had a history of smoking and chronic alcohol use,
whereas controls were somewhat more likely than cases to have used intravenous drugs.
There were no differences between cases and controls in terms of vital signs and signs of
portal hypertension and hepatic dysfunction by physical examination, other than there being
a lower probability of ascites in patients with PPHTN (Table 3). Hemoglobin was slightly
higher in cases than controls. However, white blood cell count, platelet count, and the
international normalized ratio were similar. There were no differences in total bilirubin or
total protein, although cases had a higher mean serum albumin and lower aminotransferase
levels compared to controls.
Chest radiography showed cardiomegaly and large pulmonary arteries more commonly in
the patients with PPHTN than in liver disease controls (Table 4). There were no differences
in spirometric measures between cases and controls; however, cases had lower diffusing
capacity for carbon monoxide (corrected for hemoglobin) percent predicted. Cases had
slightly higher arterial pH, lower arterial partial pressure of oxygen, and higher alveolar-
arterial oxygen gradient. Abdominal imaging confirmed a lower prevalence of ascites in
cases compared to controls; most patients in both groups had splenomegaly.
Patients with PPHTN had characteristic right-sided findings on transthoracic
echocardiography; liver disease controls (by definition) did not show right-sided
abnormalities (Table 5). Cases had somewhat more left ventricular hypertrophy, however,
left atrial size was similar between the groups. Pericardial effusion was more common in
patients with PPHTN (22%) compared to liver disease controls (6%) (P = 0.011).
Intrapulmonary shunting was significantly less common in cases (30%) than in controls
(56%) (P = 0.02).
Multivariate Analysis
We assessed the variables from Tables 1 and 2 in multivariate logistic regression (Table 6).
Female sex and autoimmune hepatitis were independently associated with an increased risk
of PPHTN. On the other hand, hepatitis C infection was associated with a lower risk of
PPHTN. Other demographics, anthropomorphics, MELD score, and medical comorbidities
were not significant predictors in the multivariate model. Model fit was adequate by the
Hosmer-Lemeshow goodness-of-fit test (P =0.62), and there were no overly influential
subjects.
An analysis incorporating patients who met the criteria for PPHTN except for having a
pulmonary capillary wedge pressure between 16 and 19 mm Hg (N = 3) showed similar
results. Inclusion of patients with abnormal right-sided echocardiographic results as controls
similarly did not alter the conclusions. A subset analysis excluding “prevalent” case patients
(N = 15) produced results consistent with the final logistic model.
Discussion
This is the first multicenter epidemiologic study of the clinical risk factors for PPHTN in
patients with severe liver disease and portal hypertension. Using a case-control design (well-
suited to study this rare disease), we have demonstrated that females with liver disease have
a higher risk than males of developing PPHTN. We have also shown that the etiology of
liver disease is important in determining the risk of this serious pulmonary vascular
complication. Patients with autoimmune hepatitis have a higher risk and patients with
hepatitis C infection have a lower risk of PPHTN than patients with other etiologies of liver
disease. Previously hypothesized factors, such as age, severity of liver disease, and medical
comorbidities, were not associated with the risk of PPHTN. Patients with PPHTN also had
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characteristic radiographic, arterial blood gas, and echocardiographic findings and were less
likely than controls to have intrapulmonary shunting.
The idiopathic and familial forms of PAH are well-known to occur more commonly in
women than in men.13,14 However, this is the first form of PAH related to an associated
condition shown to have an increased risk in women compared to men. Although PAH
associated with connective tissue disease frequently occurs in women, such diseases are as a
whole more common in women, and sex is not thought to affect the risk of PAH in this
setting.15 Prior retrospective studies of PPHTN have shown a possible overrepresentation of
women compared to men (considering the underlying demographic of portal hypertension),
but the absence of appropriate control groups has prevented a definitive statement until this
point.5,16 For example, Krowka et al. compared patients with PPHTN to liver disease
patients with pulmonary hypertension by echocardiography which did not meet the criteria
for PPHTN. These authors found no significant differences in demographics or other
variables between these two groups of patients. The discrepancy between these authors’
conclusions and ours is likely explained by differences between the control group in the
study of Krowka et al. (patients with liver disease with pulmonary hypertension determined
by echocardiography) and the control group of our study (patients with liver disease with
normal right heart morphology determined by echocardiography).
Hormone profile, pregnancy, and a tendency toward autoimmune processes are three
mechanistic factors which may explain the female sex predilection for PAH. Interestingly,
the female sex predominance in our study was independent of the underlying etiology of
liver disease, indicating that this finding was not accounted for by a predisposition to
autoimmune liver disease. These findings indicate that the biologic components of sex
differences may be an important starting point from which to understand why patients with
liver disease develop PPHTN.
Several lines of investigation have suggested that PAH has an immune etiology. First,
individuals with certain human leukocyte antigen subtypes have a higher risk of PAH than
do those with other subtypes.17,18 Second, connective tissue diseases are a well-established
risk factor for PAH. Third, antinuclear antibody titers are frequently elevated in patients
with PAH.19,20 Last, immune-mediated diseases of other organs (for example, thyroid) are
common in patients with PAH.21 We found that autoimmune hepatitis (and possibly primary
biliary cirrhosis) was associated with an increased risk of PPHTN. Therefore, in some cases,
PPHTN may be attributable not only to the presence of portal hypertension, but also to the
autoimmune process resulting in liver disease, consistent with a “two-hit” hypothesis.
Patients with hepatitis C infection were less likely to suffer from PPHTN, even after
consideration of the demographics and medical and social histories of these patients. There
may be some characteristic of the treatment for hepatitis C–associated liver disease which
decreases the risk in this population. However, we did not find differences between cases
and controls in the use of interferon at the time of evaluation, although we did not have
available data on all treatments received previously. Alternatively, there could be a direct
effect of the virus which is protective to the pulmonary vasculature. The basis of this novel
association is unknown.
The American Association for the Study of Liver Diseases currently recommends that all
patients being evaluated for liver transplantation undergo screening with transthoracic
echocardiography, due to the greatly increased perioperative risk of death for a liver
transplant recipient with untreated PPHTN.22 However, it is not established whether patients
with liver disease who are not transplant candidates warrant screening for this condition.
Given the relatively low specificity of echocardiography (that is, high false-positive rate)
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and the lack of well-studied therapies for PPHTN with documented efficacy,23-25 it is likely
premature to recommend screening for patients with liver disease who are not transplant
candidates, even if they fall into the “high-risk” subgroups in our study. On the other hand,
clinicians should have a low threshold to obtain echocardiography in patients with portal
hypertension with symptoms suggestive of PPHTN.
Certain factors that have been postulated to be linked to PPHTN were not associated with
case status in our study. Age and race/ethnicity did not differ between the groups. Cases
with PPHTN (which included prevalent patients) may have had a longer duration of liver
disease, however, there were no differences between cases and controls in terms of severity
of liver disease (that is, MELD score and previous hepatic complications, except for ascites
and encephalopathy). The placement of a portosystemic shunt or performance of
splenectomy did not affect the risk of PPTHN. Smoking and chronic alcohol use were
common in both groups.
Levels of liver aminotransferases were somewhat lower in cases than in controls, and
albumin levels were higher. However, other markers of liver function were similar between
the groups. These differences possibly reflect the different types of liver disease represented
in the two populations. The lower diffusing capacity for carbon monoxide, acid-base
abnormalities, and higher alveolar-arterial oxygen gradient in the absence of significant
differences in spirometric measures confirm other studies which have shown these
abnormalities in patients with PPHTN.26 These findings likely result from the vascular
arteriopathy and ventilation:perfusion mismatch which characterize PAH.
Patients with PPHTN had pericardial effusions more commonly than did controls. The
presence of a pericardial effusion is associated with worse survival in idiopathic PAH20,27;
the clinical implications of a pericardial effusion in PPHTN are unknown. Intrapulmonary
shunting was less common (although still relatively frequent) in cases with PPHTN than in
the liver disease controls. Pulmonary vasodilation is common in patients with advanced liver
disease and portal hypertension, and when accompanied by abnormal arterial partial
pressure of oxygen, defines hepatopulmonary syndrome. Considering the hemodynamic
profile of PPHTN, less pulmonary vasodilation would be expected in these patients;
however, the relationship of these two opposing pulmonary vascular syndromes seen in the
setting of portal hypertension remains to be clarified.
There are some limitations to our study. This is one of the largest samples of patients with
PPHTN with detailed phenotyping ever collected; however, there was a relatively small
number of cases. The predictors we describe had large effect sizes and were highly
significant, and our final multivariate model was robust to alterations in case and control
definitions, deletion of potentially influential subjects, and exclusion of prevalent subjects. It
is however possible that risk factors with smaller effect sizes may not have been detected in
our study. Information bias is possible, but we used standard data collection forms for all
patients. Although this could still be a problem (because some data were collected after case/
control status was established), the predictors in our final model (that is, sex and liver
disease diagnosis) are not easily affected by such bias. We specifically avoided inclusion of
factors which could be affected by PPHTN, such as radiographic and laboratory findings, in
our final explanatory multivariate model. Selection bias and exchangeability are always a
concern in case-control studies. However, it would appear that the liver disease controls at
each center came from the same source population as the cases by design, and the severity of
liver disease (reflected by MELD) was virtually identical between the groups, assuring the
comparability of the two groups. Echocardiography and right heart catheterization results
were interpreted locally; measurement error and misclassification are possible. However,
such misclassification would have led to bias to the null, unless such error was systematic
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and related to the risk factors demonstrated, which was unlikely. We recorded a variety of
potential risk factors for PPHTN; nonetheless, our findings could be accounted for by
another confounding variable or residual confounding.
In summary, sex and type of liver disease affect the risk of PPHTN. These are the first
clinical predictors of PPHTN ever defined. The mechanistic role of these factors in the
evolution of PPHTN in patients with portal hypertension should be examined in future
studies.
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Table 3
Physical Examination and Laboratory Results
Variable N Cases Controls P Value
Physical examination
 Body mass index, kg/m2 175 29 ± 5 28 ± 6 0.78
 Pulse, beats per minute 175 78 ± 15 75 ± 12 0.22
 Systolic blood pressure, mm Hg 173 115 ± 17 119 ± 17 0.23
 Diastolic blood pressure, mm Hg 173 68 ± 9 70 ± 11 0.34
 Room air oxygen saturation, % 158 95 ± 4 95 ± 3 0.30
 Ascites 172 5 (16%) 55 (39%) 0.01
 Lower extremity edema 174 18 (53%) 67 (48%) 0.60
 Clubbing 172 1 (3%) 9 (7%) 0.69
 Asterixis 173 2 (6%) 3 (2%) 0.25
 Spider angiomata 168 7 (21%) 39 (29%) 0.38
Laboratory results
 Blood urea nitrogen, mg/dL 173 14 [10–19] 14 [10–18] 0.95
 Creatinine, mg/dL 174 0.9 [0.8–1.1] 0.9 [0.7–1.1] 0.78
 Hemoglobin, g/dL 173 14 ± 2 13 ± 2 0.05
 Platelet count, 109/L 170 82 [66–103] 90 [67–137] 0.19
 International normalized ratio 174 1.3 [1.2–1.4] 1.2 [1.1–1.4] 0.49
 Alanine aminotransferase, U/L 174 28 [23–54] 49 [31–79] 0.002
 Aspartate aminotransferase, U/L 174 44 [35–61] 74 [47–110] < 0.001
 Total bilirubin, mg/dL 174 1.8 [1.1–2.7] 1.9[1.3–2.9] 0.67
 Alkaline phosphatase, U/L 172 114 [96–164] 140 [100–203] 0.045
 Total protein, g/dL 165 7.3 ± 0.8 7.2 ± 0.9 0.28
 Albumin, g/dL 167 3.7 ± 0.4 3.2 ± 0.7 < 0.001
Data are shown as mean ± standard deviation, median [interquartile range], or n (%).
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Table 4
Chest Radiography, Pulmonary Function Testing, Arterial Blood Gas Results, and Abdominal Imaging
Variable N Cases Controls P Value
Chest radiography
 Cardiomegaly 167 14 (45%) 7 (5%) < 0.001
 Large pulmonary arteries 167 13 (42%) 1 (1%) < 0.001
 Interstitial lung disease 167 0 4 (3%) 1.0
 Hyperinflation 167 0 1 (1%) 1.0
 Pleural effusion 167 2 (6%) 13 (10%) 0.74
Pulmonary function testing
 FVC, % predicted 162 85 ± 16 88 ± 15 0.38
 FEV1, % predicted 162 83 ± 15 88 ± 14 0.14
 FEV1/FVC 162 0.77 ± 0.07 0.78 ± 0.06 0.54
 DLCOcorr, % predicted 153 53 ± 11 62 ± 15 0.009
Arterial blood gas
pH 147 7.46 ± 0.03 7.43 ± 0.04 0.009
pCO2, mm Hg 147 32 ± 4 35 ± 5 0.02
pO2, mm Hg 147 76 ± 16 87 ± 15 0.006
Alveolar-arterial oxygen gradient, mm Hg 147 29 [14–41] 13 [6–20] 0.007
Abdominal imaging
 Splenomegaly 163 20 (80%) 103 (75%) 0.57
 Ascites 173 4 (15%) 66 (48%) 0.002
 Portal vein thrombosis 174 1 (4%) 7 (5%) 1.0
Data are shown as mean ± standard deviation, median [interquartile range], or n (%). Abbreviations: FVC, forced vital capacity; FEV1, forced
expiratory volume in 1 second; DLCOcorr, diffusing capacity for carbon monoxide corrected for hemoglobin.
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Table 5
Echocardiography Results
Variable N Cases Controls P Value
Right atrial dilation 162 24 (77%) 0 < 0.001
Right ventricular dilation 167 28 (82%) 0 < 0.001
Right ventricular hypertrophy 166 13 (41%) 0 < 0.001
Right ventricular dysfunction 167 20 (61%) 0 < 0.001
Paradoxical septal motion 152 7 (23%) 0 < 0.001
Tricuspid regurgitation 166 31 (97%) 111 (83%) 0.049
Estimated right ventricular systolic pressure, mm Hg 91 77 ± 25 30 ± 5 < 0.001
Pulmonic regurgitation 129 23 (82%) 38 (38%) < 0.001
Left atrial size, cm 137 4.1 [3.5–5.5] 4 [3.5–4.3] 0.16
Left ventricular hypertrophy 173 11 (32%) 25 (18%) 0.06
Pericardial effusion 166 7 (22%) 8 (6%) 0.011
Shunting 144 0.02
 None 13 (57%) 45 (37%)
 Intrapulmonary 7 (30%) 68 (56%)
 Intracardiac 2 (9%) 8 (7%)
 Indeterminate 1 (4%) 0
Data are shown as mean ± standard deviation, median [interquartile range], or n (%).
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Table 6
Multivariate Logistic Regression
Variable OR 95% CI P Value
Female gender 2.90 1.20–7.01 0.018
Autoimmune hepatitis 4.02 1.14–14.23 0.031
Hepatitis C infection 0.24 0.09–0.65 0.005
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